Q-omics provides the consensus-scored CMYA5 profile across patient tissues and cancer cell-line models. CMYA5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CMYA5 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CMYA5 RNA expression shows 19,681 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LGG, KICH, and BRCA as cancer lineages where CMYA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CMYA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CMYA5 survival associations across molecular data types. CMYA5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CMYA5 RNA expression–survival associations across cancer types. High CMYA5 expression shows unfavorable associations in LGG, but favorable associations in BRCA, UCS, MESO, SKCM and LUAD. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CMYA5 RNA expression.
This table summarizes CMYA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CMYA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CMYA5 shows lower tumor expression in KICH, HNSC, UCEC, BRCA, COAD and KIRP. The KICH box plot shows higher CMYA5 RNA expression in normal versus tumor tissue (log2 FC = −0.674, t-test p = .002).
This table shows molecular features associated with CMYA5 in patient tissues and cancer cell lines. In patient samples, CMYA5 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CMYA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
